Viatris (HAM:VIA) Cyclically Adjusted Revenue per Share: €18.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:VIA Viatris Inc HAM:VIA
58 GF Score
Price €15.10
GF Value €9.48
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Cyclically Adjusted Revenue per Share?

Viatris HAM:VIA +1.70% 58 Cyclically Adjusted Revenue per Share is €18.06 as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.48 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Viatris's adjusted revenue per share for the three months ended in Mar. 2026 was €2.588. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €18.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Viatris's average Cyclically Adjusted Revenue Growth Rate was -3.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Viatris was 27.20% per year. The lowest was -2.60% per year. And the median was 12.70% per year.

As of today (2026-07-16), Viatris's current stock price is €15.10. Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €18.06. Viatris's Cyclically Adjusted PS Ratio of today is 0.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viatris was 2.97. The lowest was 0.35. And the median was 0.70.


Viatris  (HAM:VIA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viatris's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.10/18.06
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viatris was 2.97. The lowest was 0.35. And the median was 0.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Viatris Cyclically Adjusted Revenue per Share Related Terms


Viatris Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Viatris's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Cyclically Adjusted Revenue per Share Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.38 21.16 20.15 20.79 17.73

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.26 18.56 17.77 17.73 18.06

HAM:VIA vs NBIX, UTHR, ELAN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PS Ratio falls into.


HAM:VIA
58GF Score
Viatris Inc HAM:VIA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viatris's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.588/330.2130*330.2130
=2.588

Current CPI (Mar. 2026) = 330.2130.

Viatris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.471 241.018 6.126
201609 5.202 241.428 7.115
201612 5.775 241.432 7.899
201703 4.736 243.801 6.415
201706 4.909 244.955 6.618
201709 4.667 246.819 6.244
201712 5.108 246.524 6.842
201803 4.213 249.554 5.575
201806 4.656 251.989 6.101
201809 4.749 252.439 6.212
201812 5.239 251.233 6.886
201903 4.288 254.202 5.570
201906 4.895 256.143 6.311
201909 5.210 256.759 6.700
201912 5.530 256.974 7.106
202003 4.585 258.115 5.866
202006 4.689 257.797 6.006
202009 4.874 260.280 6.184
202012 3.486 260.474 4.419
202103 3.082 264.877 3.842
202106 3.143 271.696 3.820
202109 3.180 274.310 3.828
202112 3.177 278.802 3.763
202203 3.137 287.504 3.603
202206 3.200 296.311 3.566
202209 3.381 296.808 3.762
202212 2.996 296.797 3.333
202303 2.889 301.836 3.161
202306 3.005 305.109 3.252
202309 3.059 307.789 3.282
202312 2.906 306.746 3.128
202403 2.787 312.332 2.947
202406 2.961 314.175 3.112
202409 2.816 315.301 2.949
202412 2.824 315.605 2.955
202503 2.525 319.799 2.607
202506 2.648 322.561 2.711
202509 2.751 324.800 2.797
202512 2.744 324.054 2.796
202603 2.588 330.213 2.588

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €18.06 mean?
Viatris (HAM:VIA) has a Cyclically Adjusted Revenue per Share of €18.06 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Viatris and its competitors.
Is Viatris' Cyclically Adjusted Revenue per Share too high?
Viatris' current Cyclically Adjusted Revenue per Share is €18.06. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Cyclically Adjusted Revenue per Share compare to NBIX and UTHR?
Viatris' Cyclically Adjusted Revenue per Share of €18.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Viatris and its competitors. Viatris's current Cyclically Adjusted Revenue per Share is €18.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.48, compared to a current price of €15.10 — trading 59.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €18.06. Viatris' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Cyclically Adjusted Revenue per Share is €18.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €15.10 is trading 59.3% above its estimated GF Value™ of €9.48. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Cyclically Adjusted Revenue per Share: €18.06
  • GF Value™: €9.48 vs. price of €15.10 (59.3% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score

Get the complete analysis for HAM:VIA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.10
Price
€9.48
GF Value